Korro Bio, Inc. (KRRO)
$12.91-$0.35 (-2.64%) Today
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 6,684 | $79K |
| Open-market sale | 26 | 352,731 | $4.91M |
| Grant or award | 10 | 115,062 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
47 Form 4 filings on record, the earliest from Oct 18, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jean Francois Formela - Director | Open-market sale | Common Stock | 249 | $13.96 | $3K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 51 | $13.96 | $712 | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 23,584 | $14.00 | $330K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 4,884 | $14.00 | $68K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 1,775 | $13.96 | $25K | |
| Jean Francois Formela - Director | Open-market sale | Common Stock | 368 | $13.96 | $5K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.001 par value per share | 5,222 | $11.40 | $60K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.001 par value per share | 1,462 | $13.19 | $19K | |
| Ram Aiyar - Officer | Open-market sale | Common Stock | 5,802 | $10.84 | $63K | |
| Loic A. Vincent - Officer | Grant or award | Common Stock | 7,500 | $0.00 | - | |
| Oliver Dolan - Officer | Grant or award | Common Stock | 5,500 | $0.00 | - | |
| Jeffrey Cerio - Officer | Grant or award | Common Stock | 6,500 | $0.00 | - | |
| Todd Chappell - Officer | Grant or award | Common Stock | 7,500 | $0.00 | - | |
| Jean Francois Formela | Open-market sale | Common Stock | 85,955 | $14.03 | $1.21M | |
| Jean Francois Formela | Open-market sale | Common Stock | 14,745 | $14.03 | $207K | |
| Jean Francois Formela | Open-market sale | Common Stock | 817 | $13.96 | $11K | |
| Jean Francois Formela | Open-market sale | Common Stock | 8,506 | $13.96 | $119K | |
| Jean Francois Formela | Open-market sale | Common Stock | 17,426 | $14.25 | $248K | |
| Jean Francois Formela | Open-market sale | Common Stock | 40,679 | $14.60 | $594K | |
| Jean Francois Formela | Open-market sale | Common Stock | 666 | $14.98 | $10K | |
| Jean Francois Formela | Open-market sale | Common Stock | 6,979 | $14.60 | $102K | |
| Jean Francois Formela | Open-market sale | Common Stock | 114 | $14.98 | $2K | |
| Jean Francois Formela | Open-market sale | Common Stock | 3,382 | $13.95 | $47K | |
| Jean Francois Formela | Open-market sale | Common Stock | 580 | $13.95 | $8K | |
| Jean Francois Formela | Open-market sale | Common Stock | 101,579 | $14.25 | $1.45M | |
| Todd Chappell - Officer | Open-market sale | Common Stock | 3,168 | $10.83 | $34K | |
| Loic A. Vincent - Officer | Open-market sale | Common Stock | 3,418 | $10.83 | $37K | |
| Jeffrey Cerio - Officer | Open-market sale | Common Stock | 6,609 | $10.83 | $72K | |
| Oliver Dolan - Officer | Open-market sale | Common Stock | 3,383 | $10.83 | $37K | |
 Ali Behbahani | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Rachel Meyers | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Nessan Bermingham | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Katharine Knobil | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Jean Francois Formela | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Timothy R. Pearson | Grant or award | Stock Option (Right to Buy) | 14,677 | $0.00 | - | |
| Ram Aiyar - Officer | Open-market sale | Common Stock | 15,152 | $12.98 | $197K | |
| Jean Francois Formela | Open-market sale | Common Stock | 2,441 | $13.95 | $34K | |
| Jean Francois Formela | Open-market sale | Common Stock | 419 | $13.95 | $6K | |
| Ram Aiyar - Officer | Grant or award | Common Stock | 50,000 | $12.33 | $617K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.001 par value per share | 520 | $10.60 | $6K | |
 Rick Yang | Open-market purchase | Common Stock | 207,100 | $11.11 | $2.30M | |
| Rick Yang | Open-market purchase | Pre-Funded Warrants | 242,945 | $11.11 | $2.70M | |
 Scott D. Sandell | Open-market purchase | Pre-Funded Warrants | 242,945 | $11.11 | $2.70M | |
| Scott D. Sandell | Open-market purchase | Common Stock | 207,100 | $11.11 | $2.30M | |
| New Enterprise Associates 17, L.P. | Open-market purchase | Common Stock | 207,100 | $11.11 | $2.30M | |
| New Enterprise Associates 17, L.P. | Open-market purchase | Pre-Funded Warrants | 242,945 | $11.11 | $2.70M | |
 Carmen Chang | Open-market purchase | Pre-Funded Warrants | 242,945 | $11.11 | $2.70M | |
| Carmen Chang | Open-market purchase | Common Stock | 207,100 | $11.11 | $2.30M | |
| Ali Behbahani | Grant or award | Common Stock | 207,100 | $11.11 | $2.30M | |
| Ali Behbahani | Grant or award | Pre-Funded Warrants | 242,945 | $11.11 | $2.70M |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Atlas Venture Opportunity Fund II, L.P. | Shareholder | 51 | $700 | View on EDGAR | |
| Atlas Venture Fund XI, L.P. | Shareholder | 249 | $3K | View on EDGAR | |
| Atlas Venture Opportunity Fund II, L.P. | Shareholder | 4,884 | $65K | View on EDGAR |
Korro Bio, Inc. (KRRO) had 23 insider filings in the last 90 days, with the most recent on 2026-08-28. The full record for KRRO runs to 47 Form 4 filings, the earliest from 2024-10-18. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of KRRO were filed in the last 90 days, totaling $79K.
26 insider sales of KRRO were filed in the last 90 days, totaling $4.91M.
This page tracks KRRO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add KRRO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
